The global gene panel market is witnessing significant transformation driven by technological advancements and increasing application in personalized medicine. This industry is experiencing accelerated business growth amid rising demand for accurate genetic testing, which is reshaping market trends and expanding the overall market scope.
Market Size and Overview
The global gene panel market is estimated to be valued at US$ 22,044.7 Mn in 2021, and is expected to exhibit a CAGR of 20.2% over the forecast period (2021-2028).
Gene Panel Market Growth is propelled by expanding adoption of gene panel testing in oncology, rare diseases, and inherited disorders. The increasing market revenue reflects robust industry dynamics and strong market opportunities, positioning this segment for continued growth.
Market Drivers
- Technological Innovations Fueling Market Growth: One of the key market drivers is the rapid advancement in next-generation sequencing (NGS) technologies and bioinformatics tools. In 2024, Illumina Inc. launched an enhanced gene panel testing platform that reduced turnaround time by 30%, significantly improving diagnostic precision. This has accelerated market penetration, particularly in oncology diagnostics, driving higher market revenue and enhancing the market company’s competitive position.
- Growing awareness among healthcare providers and patients about genomic profiling is further intensifying market demand, enabling market players to capitalize on emerging market opportunities.
PEST Analysis
- Political: Regulatory reforms in the US and Europe, including faster approvals by the FDA and EMA for genetic diagnostics in 2024, have enhanced market scope, promoting investments in gene panel technologies.
- Economic: Increased government funding and private-sector investments, such as the $150 million gene therapy grant announced in 2025, have led to expanded market revenue and stimulated market growth strategies for developmental innovation.
- Social: Rising patient preference for precision medicine and growing public awareness campaigns on genetic disorders by various organizations in 2025 have positively influenced market demand, contributing to greater industry size and market share.
- Technological: Continuous upgrades in sequencing technologies and data analytics tools, exemplified by QIAGEN's AI-driven gene panel solution introduced in 2024, are shaping market trends and driving competitive differentiation among market players.
Promotion and Marketing Initiative
Recent promotion and marketing initiatives in the gene panel market have focused on direct engagement with healthcare professionals and strategic collaborations. For instance, in 2025, Thermo Fisher Scientific Inc. launched a global awareness campaign targeting oncology specialists, integrating educational webinars and real-world clinical case studies. This initiative boosted product adoption rates by 25%, positively impacting market share and reinforcing brand presence in key geographies. Such targeted marketing strategies continue to open new market segments and enhance business growth.
Key Players
- Thermo Fisher Scientific Inc. recently expanded its gene panel portfolio focusing on rare diseases, increasing their market revenue by 18% in 2024.
- BGI enhanced its genetic sequencing capabilities, partnering with healthcare networks in Asia to broaden market share across emerging markets.
- GENEWIZ, Inc. launched custom gene panel solutions tailored for cancer diagnostics in 2025, resulting in a 22% increase in client acquisitions.
- GATC Biotech expanded its service network in Europe, improving accessibility and market footprint.
- Novogene Co., Ltd. invested in AI-based data interpretation platforms, streamlining operations and accelerating market growth.
- QIAGEN introduced advanced NGS panels integrated with AI for faster analysis in 2024, increasing competitive edge.
- Integrated DNA Technologies, Inc. strengthened collaborations with pharmaceutical companies for companion diagnostics.
- Illumina Inc. reported a 30% enhancement in throughput for gene panel assays, driving increased industry size.
- Agilent Technologies, Inc. launched integrated liquid biopsy panels enhancing market opportunities in oncology.
- Eurofins Scientific expanded clinical trial solutions based on gene panels to accelerate drug development.
- F. Hoffmann-La Roche Ltd introduced multi-disease gene panels increasing clinical adoption.
- Personalis Inc. partnered with research institutes to co-develop novel gene panels in rare oncology indications.
- GeneDx Inc. focused on expanding pediatric genetic testing panels, increasing their market report visibility.
- Invitae Corporation diversified product offerings with population genetics panels, supporting wider Gene Panel Market penetration.
FAQs
1. Who are the dominant players in the gene panel market?
Leading market companies include Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, BGI, and Novogene Co., Ltd., all driving innovation through product launches and strategic partnerships in 2024 and 2025.
2. What will be the size of the gene panel market in the coming years?
The gene panel market size is forecasted to grow from USD 22,044.7 million in 2025 to nearly USD 29,975.8 million by 2032, growing at a robust CAGR of 20% reflecting strong market revenue growth and expanding market scope.
3. Which end-user industry has the largest growth opportunity?
Oncology represents the largest growth segment within the gene panel market due to increasing demand for personalized cancer therapies and advancements in molecular diagnostics.
4. How will market development trends evolve over the next five years?
Market trends point toward increased integration of AI and machine learning in gene panel diagnostics, faster sequencing turnaround times, and broader adoption in rare disease diagnosis contributing to expanding market dynamics.
5. What is the nature of the competitive landscape and challenges in the gene panel market?
The competitive landscape is characterized by intense innovation-focused competition with challenges including high costs of technology and regulatory complexities. Companies adopting aggressive product development and strategic collaborations are better positioned to overcome these restraints.
6. What go-to-market strategies are commonly adopted in the gene panel market?
Key strategies include direct engagement with healthcare professionals, educational campaigns, partnerships with clinical research networks, and expanding customized gene panel offerings tailored to regional market needs, enhancing market share and business growth.
---
‣ Get More Insights On: Gene Panel Market Growth
‣ Get This Report In Japanese Language: 遺伝子パネル市場
‣ Get This Report In Korean Language: 유전자패널시장
‣ Read More Related Articles: The Role of Genomics Companies in Advancing Biotechnology: Collaborations and Partnerships
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
